# Managing OA of the Knee and Hip: From Injections to Joint Replacement. An evidence based talk

Jared RH Foran, MD

30<sup>th</sup> Annual Metabolic Bone Disease
Society Meeting



## Disclosures

- Consultant Zimmer Biomet
- Consultant AIC



## Outline

- OA:
  - Types
  - Causes
- Pathophysiology
- Diagnosis
- Treatment (KNEE and then HIP)
  - Non-operative measures
  - Operative measures





# Osteoarthritis (OA)

- Osteoarthritis is a non-inflammatory,
   degenerative condition of joints characterized by degeneration of articular cartilage and formation of new bone osteophytes
  - Common in weight-bearing joints such as hip and knee, but can affect any joint




### **OA Risk Factors**

- Hereditary
- Female gender
- Aging
- Obesity (knee)
- Abnormal mechanical loading
  - meniscectomy, instability
- Inherited type II collagen defects
- Joint injury
  - Trauma
  - Infection:
  - Crystalline arthropathy
  - Multiple hemarthroses (hemophillia)





## Classification of OA





## Primary OA

- More common than secondary OA
- Cause Unknown
  - Genetic—multifactorial
  - Congenital (alignment issues)
- Common in elderly where there is no previous pathology.
- Its mainly due to wear and tear changes occurring in old ages mainly in weight bearing joints



# Secondary OA

- Due to a predisposing cause such as:
- Trauma
- latrogenic (previous meniscectomy)
- Infection
- Inflammatory arthritis (RA)
- Crystalline arthropathy
- Congenital hip dysplasia (CDH)
- Deformity
- Obesity
- Other disease: hemophilia, hyperthyroidism, etc.





# Pathophysiology

- Cartilage erosion often central/weight bearing areas.
- Fibrillation leads to softening, splitting and fragmentation of the cartilage in both weight bearing & non-weight bearing areas.
- Collagen fibers split with disorganization
   of the proteoglycan/H20/collagen relationship, which
   causes further softening and flaking
- These flakes of cartilage may break off and impact the joint surfaces causing locking and inflammation




# Pathophysiology

- Interleukin-1 (IL-1) is a potent pro-inflammatory cytokine that, in vitro, is capable of inducing chondrocytes and synovial cells to synthesize Matrix Metallo Proteinases (MMPs).
- These MMPs are the primary enzymes responsible for the degradation of articular cartilage.
- IL-1 suppresses the synthesis of type II collagen and proteoglycans, and inhibits the transforming growth factor-ß stimulated chondrocyte proliferation.



# Diagnosis

- So Easy even an orthopod can do it!
  - History
  - Physical Exam
  - Imaging
  - Sorry folks... no labs!





# History

- Pain
- Stiffness (often first thing patients notice)
- Deformity (knee)
- Instability (knee)
- Muscle weakness or atrophy
- Joint enlargement
- Crepitus
- Effusion (knee)






## Pearls of OA Wisdom

- Knee OA hurts in the knee
  - Beware the radiating knee pain
- Hip OA hurts in the groin, thigh, and knee!
  - Patients often DO NOT KNOW WHERE THE HIP IS!
  - PCP's may know but not ask?




# Pearls (Back Pain)





## Pearls (Trochanteric Bursitis)







# Pearls (True Hip Pain)

- Don't think "groin pull" Think hip OA!
- Knee pain... Always consider hip as source!





## Physical Exam

- Hip:
  - Antalgic gait (limp)
  - Loss of motion
  - Pain with motion(internal rotation!)
- Knee
  - Antalgic gait
  - Loss of motion
  - Contractures
  - Pain with motion
  - Varus/valgus deformity
  - Joint effusion
  - Enlargement (osteophytes)
  - Crepitus/Patellar grind
  - Popliteal (Baker's) Cyst
  - Pain with hip motion



# **Imaging**

- Radiographs
- MRI





## Pearls of Wisdom

Do This...












# Radiographs (WEIGHT BEARING!)









## Pearls of Wisdom

Do This...




Not This...





## **Evidence-Based Treatment**





### The basis of the evidence




#### TREATMENT OF OSTEOARTHRITIS OF THE KNEE

EVIDENCE-BASED GUIDELINE 2<sup>ND</sup> EDITION

Adopted by the American Academy of Orthopaedic Surgeons Board of Directors May 18, 2013



## **Knee Treatment**





# Knee: Non-pharmacologic treatment

- Self management (exercise, PT, neuromuscular education)
- Rest/activity modification
- Assistive device (cane, walker)
- Weight loss
- Acupuncture
- TENS
- Manipulation(massage, chiropractic, myofascial release)
- Unloader bracing
- Shoe wedges (orthotics)
- Glucosamine/Chondroitin
- Psychosocial support



# Knee: Non-operative: Non-Pharmacologic

- Recommended:
  - Low Impact Exercise (AAOS strong evidence)
  - Weight loss (moderate evidence)



- Glucosamine and Chondroitin (strong evidence)
- Acupuncture (strong evidence)
- Shoe wedges (moderate evidence)
- TENS (strong evidence)

#### Inconclusive:

- Physical (manual therapy)
- Unloader bracing



TREATMENT OF OSTEOARTHRITIS OF THE KNEE

EVIDENCE-BASED GUIDELINE 2<sup>ND</sup> EDITION

Adopted by the American Academy of Orthopaedic Surgeons Board of Directors May 18, 2013




# Other Non-Pharmacologic treatments

- Not Covered by AAOS guidelines (common sense?):
  - Rest (activity modification)
  - Assistive device (cane, walker)
  - Psychosocial support



## **Knee Treatment**





# Knee: Non-operative Pharmacologic

- NSAIDs (oral or topical)
- Acetaminophen
- Tramadol
- Opioids
- Pain patches
- CBD creams






# Knee: Non-operative: Pharmacologic

- Recommend:
  - NSAIDS
    - Oral or topical (strong evidence)
    - (Tramadol?)
- Inconclusive
  - (acetaminophen?)
  - pain patches
  - (opioids!)






# How about Cannabidiol (CBD)?





## **Knee Treatment**





# Non-operative: Procedural

- Corticosteroid injections
- Hyaluronic acid injections
- Needle Lavage
- Prolotherapy
- PRP
- Stem cells





# Non-operative: Procedural

- Inconclusive:
  - Corticosteroids
  - PRP, growth factors



- Cannot Recommend:
  - Hyaluronic acid (strong evidence)
  - Joint lavage (prolotherapy?) (moderate evidence)




## Stem Cells?

- Tremendous interest
  - Patients
  - Practitioners
  - Media
- Tremendous Cost
  - Patients
- Tremendous Profits
  - Practitioners
- Tremendously POOR evidence






## **Knee Treatment**





## **Operative Treatment Knee**

- Cannot Recommend
  - Arthroscopy (strong evidence)
  - Interpositional arthroplasty (consensus)










#### **Operative Treatment**

#### Consider:

- Proximal tibial osteotomy (Limited evidence)
  - Appropriate for the very young
  - Milder OA
- Very painful
- Limited expectations





## Operative Treatment of knee OA


- Total knee arthroplasty
- Unicompartmental knee arthroplasty




#### Operative Treatment: Total Knee Replacement

- "Total Knee Arthroplasty"
- Has been around since 1960's
- One of the most successful operations in all of medicine
- Knee "resurfacing" is more appropriate term
- The damaged cartilage surface is removed and resurfaced with metal caps with a plastic spacer in between













• Step 1: Remove damaged cartilage from the

femur




Step 2: Remove damaged cartilage from the

Tibia






• Step 3: Remove Damaged cartilage from the Patella (knee cap)







• Step 4: Cap the Femur



• Step 5: Cap the Tibia



• Step 6: Cap the Patella





Now you are done





# Total Knee Replacement

**Before** After









#### How Long do they Last?

- Howell SM et al. Implant Survival and Function Ten Years After Kinematically Aligned Total Knee Arthroplasty. J Arthroplasty. 2018
  - 98% survivorship at 10 years
- Lachiewicz, P. et al. Fifteen-year survival...modular posterior stabilized knee replacement. A concise follow-up of a previous report. *J Bone Joint Surg Am*, 91(6): 1419-23, 2009.
  - 90.6% of knees doing well at 15 years.
- Abdeen, A et al. Fifteen-year to 19-year follow-up of the Insall-Burstein-1 total knee arthroplasty. J Arthroplasty,;25(2):173-8. 25(2): 173-8. 2010
  - 92.4 % of knees doing well at 19 years



#### Osteoporosis and TKA

- **Spinarelli** A, et al. <u>Total knee arthroplasty in elderly osteoporotic patients.</u> Aging Clin Exp Res. 2011 Apr;23(2 Suppl):78-80. Review.
- 100 consecutive total knees in osteoprotic patients (mean age 77)
- Summary: outcomes rivaled that of comparable series of nonosteoporotic patients




#### Osteoporosis and TKA

- Suzuki T, et al. Teriparatide Administration Increases Periprosthetic Bone Mineral Density After Total Knee Arthroplasty: A Prospective Study. <u>J Arthroplasty.</u> 2018 Jan;33(1):79-85
  - 22 TKA/osteoporosis patients compared to controls
  - Measured BMD by DEXA at baseline, 6 months and 12 months after knee replacement.
  - Preserved or improved periprosthetic bone quality compared to controls



## Teriparatide: Miracle Drug?

Suzuki T, et al. Teriparatide Treatment Improved Loosening of Cementless Total Knee Arthroplasty: A Case Report. <u>J Orthop Case</u> Rep. 2017 Jan-Feb;7(1):32-35.






# Operative Treatment: Partial Knee Replacement






# Partial Knee Replacement Medial or Lateral Partial:





# Partial Knee Replacement Knee Cap (Patellofemoral)



## Partial Knee Replacement

- Advantages:
  - Less invasive surgery
    - Easier, faster recovery
  - Preserves your native bone and ligaments
    - May feel more like your native knee
- Disadvantages
  - May have residual pain in other compartments
  - May develop pain *later* in other compartments



#### Partial or total solution?

- A "partial" knee is not a "partial" solution!
- **Foran**, et al. Long-term survivorship and failure modes of unicompartmental knee arthroplasty. Clin Orthop Relat Res. *102-8*; 2013
  - 93% of knees doing well at 15 years and 90% doing well at 20 years
- Foran JR, Sheth NM, Della Valle, CJ. Long Term Patellofemoral Progression. Textbook Chapter 21 Partial Knee Arthroplasty: Techniques for Optimal Outcomes,). 2012.

### Treatment Hip OA



#### MANAGEMENT OF OSTEOARTHRITIS OF THE HIP EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE

Adopted by the American Academy of Orthopaedic Surgeons Board of Directors 3.13.17

Endorsed by:










# Evidence Based Treatment



Feel Better. Do More.

303-233-1223 PanoramaOrtho.com



#### Hip: Non-operative:

- Recommended:
- Weight loss (AAOS moderate evidence)
- Non-narcotic management (strong)
- Physical Therapy (Strong)
  - For mild/moderate OA
- Glucosamine (moderate)
  - Only analyzed 1 of 85 studies!
- Intraarticular cortisone (strong)
- Not Recommended
  - Hylaruonic acid injections (strong)



#### MANAGEMENT OF OSTEOARTHRITIS OF THE HIP EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE

Adopted by the American Academy of Orthopaedic Surgeons Board of Directors 3.13.17

Endorsed by







## Total Hip Replacement

- Developed in 1960's
- Also one of the most successful operations in all of medicine
- Advances in implant materials and surgical techniques have led to longevity of hip replacements




# Many Ways to Skin a Cat

- Anterior
- Anterolateral
- Direct Lateral
- Posterolateral
- Posterior

- Many approaches
- All have pros/cons
- All have been around for a long time
- No clear advantage in the literature











# Total hip replacement: before and after







# Total Hip Replacement

**Before** 



#### After







# How long Will it Last? Hips

- Sochart DH, Porter ML. The long-term results of Charnley low-friction arthroplasty in young patients... J Bone Joint Surg Am. 1997
  - 81.5% doing well at 25 years!

Vidalain J-P. Twenty-year results of the cementless Corail stem. International Orthopaedics. 2011

- -modern cementless hip design
- -82.5% doing well at 23 years.

(Neither of these long term studies utilize modern materials)

- De Steiger. R Cross-Linked Polyethylene for Total Hip Arthroplasty Markedly Reduces Revision Surgery at 16 Years. J Bone Joint Surg Am. 2018
  - 94% survivorship at 16 years!



#### Osteoporosis and THA

- Hung, et al. Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study. <u>Arch Osteoporos.</u> 2018 Oct 10;13(1):107
- 35,870 patients with hip osteoarthritis and osteoporosis
- 3162 and 1667 respectively treated with bisphosphonates and other non-bisphosphonates AOM respectively
- Outcome: risk of needing THA same in all patients.



#### A Role for AOM's?

- Nagoya S et al. Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty. <u>Eur J Orthop Surg Traumatol.</u> 2018 May 17.
- Prospective study
- Cementless THA. 10 patients received denosumab versus control
- Findings: up to 7.3% increase in periprosthetic BMD in treatment group



### Summary

- OA: progressive degenerative condition
  - Large genetic component
  - Complex pathophysiology
  - Non-operative treatments: perhaps not evidence based
  - Increasing role for metabolic treatments
- Pearls:
  - Weight-bearing radiographs BEFORE MRI!
  - Hip pain: groin, thigh, knee
  - Avoid opioids for chronic treatment
  - Long term survivorship for modern TKA and THA



#### Thanks!





